Sun Pharma Nears Record $9.4 Billion Organon Acquisition After Shareholder Approval

Sun Pharmaceutical Industries Ltd. has moved closer to completing its largest-ever acquisition after Organon shareholders approved the proposed merger, marking a major milestone in the transaction announced earlier this year. The acquisition, valued at approximately $9.4 billion, including debt, is expected to close by early 2027, subject to remaining customary conditions, including regulatory approvals.

The deal surpasses Sun Pharma's landmark 2014 acquisition of Ranbaxy Laboratories, making it the biggest acquisition in the company's history. Once completed, the transaction is expected to strengthen Sun Pharma's global pharmaceutical business by expanding its portfolio beyond specialty medicines and generic drugs while increasing its presence in developed markets.

Investors have been closely tracking the acquisition because it represents one of the largest outbound healthcare deals by an Indian pharmaceutical company. The addition of Organon's portfolio is expected to diversify Sun Pharma's revenue base through established medicines and women's healthcare products that generate relatively stable cash flows.

Organon Shareholders Approve Proposed Merger

Organon shareholders have voted in favour of the proposed acquisition by Sun Pharmaceutical Industries Ltd., clearing another important step before the transaction can be completed.

Sun Pharma said the shareholder approval represents an important milestone toward closing the acquisition. However, the transaction still requires the fulfilment of remaining customary closing conditions, including approvals from regulatory authorities across relevant jurisdictions.

The company has not indicated any change to its previously announced timeline and continues to expect the acquisition to close during early 2027.

Deal Value and Transaction Structure

The proposed acquisition carries an enterprise value of approximately $9.4 billion, including debt.

Following completion of the transaction, Organon will become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA Inc., an indirect wholly owned subsidiary of Sun Pharmaceutical Industries.

Acquisition Snapshot

Particulars	Details
Acquirer	Sun Pharmaceutical Industries Ltd.
Target Company	Organon
Deal Value	Approximately $9.4 billion (including debt)
Announcement	April 2026
Shareholder Approval	Received
Expected Completion	Early 2027
Pending Requirement	Regulatory approvals and customary closing conditions

Why the Acquisition Matters for Sun Pharma

The acquisition forms a key part of Sun Pharma's strategy to broaden its international business and diversify its product portfolio.

Organon operates across women's health, biosimilars and established medicines, areas that complement Sun Pharma's existing pharmaceutical business. The acquisition is also expected to strengthen the company's presence in developed healthcare markets while reducing dependence on a narrower mix of therapeutic segments.

By adding a portfolio of mature brands with established demand, Sun Pharma aims to improve the stability of its global revenue streams and strengthen its long-term business profile.

About Organon

Organon was created as an independent pharmaceutical company after being spun off from Merck & Co. in 2021.

The company markets products across multiple therapeutic categories, with a strong presence in:

• Women's health
• Biosimilars
• Established pharmaceutical brands

Its diversified global portfolio and presence across multiple international markets make it a strategic addition to Sun Pharma's international operations.

Sun Pharma's Biggest Acquisition to Date

The proposed Organon transaction will overtake Sun Pharma's Ranbaxy Laboratories acquisition in 2014, which had previously been the company's largest acquisition.

Over the past decade, Sun Pharma has expanded its global operations through acquisitions, specialty medicines and investments in research and development. The Organon acquisition represents another significant step in strengthening its international business footprint.

Management Commentary

Commenting on the development, Sun Pharma said the shareholder approval marks an important milestone towards completing the proposed transaction.

The company added that Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA Inc. once all remaining conditions, including regulatory approvals, have been satisfied.

What Investors Should Watch

Although shareholder approval has been secured, investors will continue monitoring several factors before the acquisition is completed.

These include:

• Regulatory approvals across relevant jurisdictions.
• Completion of customary closing conditions.
• Integration strategy after the acquisition closes.
• Financial impact on Sun Pharma's earnings and revenue mix.
• Management's guidance on expected synergies.

Any updates on these areas could influence investor sentiment as the transaction progresses toward completion.

Key Highlights

Parameter	Details
Company	Sun Pharmaceutical Industries Ltd.
Target	Organon
Deal Value	$9.4 billion (including debt)
Largest Acquisition	Yes
Previous Largest Deal	Ranbaxy Laboratories (2014)
Strategic Focus	Women's Health, Biosimilars & Established Medicines
Shareholder Approval	Received
Expected Closing	Early 2027
Pending Approvals	Regulatory clearances

Why is Sun Pharma acquiring Organon?

Sun Pharma plans to expand its global pharmaceutical business by strengthening its presence in women's health, biosimilars and established medicines while increasing its exposure to developed markets.

How much is the Organon acquisition worth?

The proposed acquisition is valued at approximately $9.4 billion, including debt, making it the largest acquisition in Sun Pharma's history.

Has the acquisition been completed?

No. Organon shareholders have approved the transaction, but the deal remains subject to regulatory approvals and other customary closing conditions before completion.

When is the acquisition expected to close?

Sun Pharma expects the transaction to close in early 2027, provided all remaining approvals and conditions are satisfied.

Why is this acquisition important for investors?

The acquisition is expected to diversify Sun Pharma's global revenue mix, strengthen its international business and expand its portfolio in women's health, biosimilars and established medicines.

What was Sun Pharma's previous biggest acquisition?

Before the Organon deal, Sun Pharma's largest acquisition was Ranbaxy Laboratories in 2014.